GLAUCOMA · White paper
Glaucoma Clinical Trials
Approved therapies, the pivotal-trial endpoints they were judged on, the magnitude of benefit — and the drugs that failed their endpoints, and why.
Indication overview
About glaucoma — and why its trials are hard
Glaucoma is a progressive optic neuropathy and a leading cause of irreversible blindness worldwide, most commonly primary open-angle glaucoma (POAG) but also angle-closure, normal-tension, and secondary forms. Elevated intraocular pressure (IOP) is the principal modifiable risk factor, though optic-nerve and visual-field damage can occur at normal pressures, so modern diagnosis integrates OCT-based nerve-fiber imaging and visual fields rather than IOP alone. Lowering IOP remains the only proven way to slow progression. The pharmacologic armamentarium spans prostaglandin analogs (latanoprost, bimatoprost), beta-blockers (timolol), alpha-2 agonists (brimonidine), carbonic anhydrase inhibitors (dorzolamide), the newer Rho-kinase inhibitor netarsudil, and the sustained-release bimatoprost implant Durysta. Trials are slowed by glaucoma's gradual progression, individual variability, reliance on IOP as a surrogate, and the need for long follow-up; adequately powered, long-term studies with structural and functional endpoints are essential. Several candidates, including memantine and trabodenoson, failed to beat placebo, underscoring the difficulty of moving beyond IOP-lowering to neuroprotection.
Approved therapies & pivotal evidence
What's been approved — and by how much it moved the endpoint
| Drug (brand) | Approved | Setting | Pivotal trial | Primary endpoint | Magnitude of benefit |
|---|---|---|---|---|---|
| Latanoprost (Xalatan) | 1996 | First-line topical therapy for elevated IOP in OAG/ocular hypertension | Pivotal comparative IOP trials | Prostaglandin analog increasing uveoscleral outflow; substantial once-daily IOP reduction (commonly ~25-35% from baseline) | |
| Timolol (Timoptic) | 1978 | Topical beta-blocker for elevated IOP | Historical pivotal and active-comparator trials | Reduces aqueous humor production; roughly 6 mmHg IOP reduction; systemic beta-blockade cautions | |
| Brimonidine (Alphagan) | 1996 | Topical alpha-2 agonist for elevated IOP | Comparative trials vs timolol | Decreases aqueous production and increases uveoscleral outflow; ~4-6 mmHg IOP reduction | |
| Bimatoprost (Lumigan) | 2001 | First-line prostaglandin analog for OAG/ocular hypertension | 12-month pivotal IOP trials | Up to ~7.5 mmHg reduction from an average baseline IOP of ~23.5 mmHg with once-daily dosing | |
| Netarsudil (Rhopressa) | 2017 | Once-daily Rho-kinase inhibitor for elevated IOP | ROCKET pivotal trials | First-in-class ROCK inhibitor increasing trabecular outflow; non-inferior IOP-lowering to timolol in defined baseline ranges | |
| Bimatoprost implant (Durysta) | 2020 | First intracameral biodegradable sustained-release implant for OAG/ocular hypertension | ARTEMIS pivotal trials | Sustained IOP reduction from a single implant, addressing topical-adherence limitations (single administration per eye per label) |
Where trials have failed
Drugs that missed their endpoint — and what contributed
The most instructive lessons in glaucoma development come from programmes that failed the endpoint that mattered.
| Drug / trial | Endpoint outcome | What contributed |
|---|---|---|
| Memantine — Neuroprotection program (NCT00141882) | Not effective in preventing glaucomatous progression | NMDA antagonist neuroprotection hypothesis failed to translate into slowed disease progression |
| Trabodenoson — MATrX-1 / Phase III (NCT02565173) | Safe but not superior to placebo across all 12 time points for IOP reduction | Adenosine A1 agonist; insufficient IOP-lowering separation from placebo |
| Oral antioxidant supplementation — Antioxidant OAG study (Oftan Macula-type program) | Not effective in patients with open-angle glaucoma | Oral antioxidant approach did not alter glaucoma outcomes |
Choosing the right endpoint
Primary endpoints that matter in glaucoma trials
- Intraocular pressure (IOP) reduction — Magnitude of IOP lowering from baseline (mmHg); primary regulatory endpoint and the only proven modifiable driver of progression
- Visual field progression — Development or worsening of scotomas on perimetry; direct measure of functional vision loss but slow to change
- Optic nerve / RNFL structure — OCT-measured retinal nerve fiber layer and optic-nerve-head changes; structural progression marker
- Rate of disease progression — Longitudinal change in structure/function; requires long follow-up given slow progression
- Safety and tolerability — Ocular surface disease and systemic effects (e.g., beta-blocker cardiovascular effects) driving adherence
How iNGENū runs glaucoma trials
Physician-led design, built for FDA submission
Endpoint & biomarker strategy
Board-certified specialists design endpoints and patient selection aligned to current FDA guidance for this indication.
FDA-ready data
Built to ICH-GCP and 21 CFR 312.120, with direct FDA submission — data accepted by the FDA, EMA and MHRA.
Faster, lower-cost delivery
~4-week ethics via the TGA CTN scheme, up to 43.5% R&D rebate, and 80–90% below US CRO cost.
The full white paper: approved-product analyses, pivotal endpoints and trial-design strategy. Open-access · no sign-in.
Frequently asked questions
Glaucoma clinical trials — FAQs
Why is lowering eye pressure the main goal if glaucoma can occur at normal pressure?
What newer options exist beyond traditional eye drops?
What makes glaucoma trials especially challenging?
Ready to discuss your glaucoma trial?
Talk to our physician-led team about an FDA-ready, cost-efficient trial design.
Request a proposal